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Abstract. The cyclic somatostatin analog, octreotide, forms
the mainstay of medical treatment for acromegaly. In addi-
tion  to lowering  circulating growth hormone levels and
shrinking tumor size, octreotide may provide symptomatic
relief of headaches associated with growth hormone secret-
ing tumors. The majority of reported complications of oc-
treotide therapy are gastrointestinal and metabolic. The
present case illustrates the development of acute bilateral
cavernous sinus syndrome with loss of eye movement bilat-
erally during octreotide therapy. Serial MRI examination
suggest tumor infarction as the etiology. The symptoms
resolved over 2 months as the tumor shrunk in size and
growth hormone was dramatically reduced.
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Introduction
While transsphenoidal surgical removal of growth hor-
mone secreting pituitary adenomas remains the treat-
ment of choice, medical care of acromegaly both pre
and post-operatively is focused  on octreotide treat-
ment [1]. Octreotide, a long-acting somatostatin ana-
log, lowers elevated growth hormone (GH) and insulin-
like growth factor-I (IGF-I)  levels in patients with
acromegaly [2], and reduces the size of GH secreting
tumors [2,3]. Because of this, octreotide has been pro-
posed as a primary pharmacological treatment for pa-
tients with GH secreting tumors, including tumors
with extensive involvement of the cavernous sinus [3].
The mechanism for octreotide’s reduction in tumor size
is hypothesized to be a reversible reduction in the size
of individual tumor cells rather than cell death [4].
Symptoms of acromegaly including soft tissue en-
largement, increased perspiration, fatigue, joint pain,
cardiomyopathy, and sleep apnea may respond to oc-
treotide therapy. The mechanism whereby octreotide
effects most of these changes is linked to reduced GH
and IGF-I levels. However, the mechanism of oc-
treotide induced headache relief remains controver-
sial, because analgesia occurs rapidly and occasionally
without any reduction in hormone levels [5,6]. It is
possible that octreotide acts therapeutically through
mechanisms other than GH and IGF-I reduction. Some
authors have proposed an opiate receptor mediated
mechanism [7] while others have proposed vasoactive
mechanisms of analgesia [8]. However, several authors
have dismissed an opiate mediated mechanism both
because octreotide acts pharmacologically as an opioid
antagonist and because naloxone fails to influence oc-
treotide induced headache reduction [9,10].
Octreotide therapy has been reported to cause gas-
trointestinal side effects such as flatulence, nausea, ab-
dominal cramping, diarrhea, malabsorption, and gall-
stone formation [11,12]. The following case report is, to
our knowledge, the first association of octreotide with
somatotropinoma infarction resulting in bilateral cav-
ernous sinus syndrome (CSS).
Case Report
A 12-year-old girl presented in July 1999 with gradu-
ally progressive headaches over a 3 month period. Her
headaches were intermittently accompanied by emesis
and subjective visual changes described as “eye shad-
owing.” In addition, the patient had experienced a dra-
matic growth  spurt with an accompanying enlarge-
ment of shoe size. A brain MRI scan revealed a
pituitary macroadenoma extending bilaterally into the
cavernous sinuses and the suprasellar cistern. Formal
visual field testing revealed no deficit. Endocrine stud-
ies revealed GH of 33.5  ng/ml (normal , 5 ng/ml),
plasma IGF-I of 924 ng/ml (normal 5 116–270 ng/ml),
and a prolactin (PRL) of 8142 ng/ml (normal 5 1–17
ng/ml).
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On a regimen of 1 mg of cabergoline twice per week,
the patient had experienced a decrease in headache
intensity with persistent episodes of emesis and a re-
duction in PRL to 4156 ng/ml at 4 weeks and to 2892
ng/ml at 6 weeks. Repeat MRI (Figure 1A) revealed no
reduction in tumor size, and the GH level remained
elevated at 54 ng/ml (Table 1). Persistence of head-
aches prompted addition of narcotic analgesia.
A transnasal transsphenoidal resection of the ade-
noma was attempted on December 8, 1999. The fibrous
consistency of the tumor prevented substantial resec-
tion and only a limited subtotal resection was obtained.
The patient tolerated the procedure well. Post-opera-
tive physical examination revealed intact cranial nerve
function with grossly intact visual fields. There was no
evidence of cerebrospinal fluid nasal drainage. The pa-
tient continued to complain of severe headache and
nausea, and was treated with narcotic analgesics, an-
tiemetics, and hydrocortisone. There was no evidence
of postoperative diabetes insipidus or SIADH. Postop-
erative MRI revealed no change in the size of the
macroadenoma (Fig. 1B).
On the evening of December 13, the patient was
begun on a regimen of 200 lg subcutaneous octreotide
every 8 hours. Headaches vanished within 3–5 minutes
but recurred within 4 hours. As a result, octreotide was
continued at 200 lg every 4–6 hours. Nonetheless,
headaches continued to recur between the injections.
GH levels on the following morning were noted to be
substantially elevated to 258 ng/ml immediately pre-
ceding the 9 AM dose of octreotide and increasing to
388 ng/ml four hours later (Table 1).
At 6 PM on December 14th, the patient’s urine out-
put increased to one liter over an hour and she was
noted to develop acute bilateral CSS. Physical exami-
nation revealed near complete bilateral sixth and third
nerve palsies with severe bilateral ptosis as well as
fixed and constricted pupils. The patient remained at
her baseline mental status with intact facial sensation.
Systolic blood pressure preceding the onset of CSS
remained in the range of 120 to 130 mmHg, with no
hypotensive or hypertensive episodes. Prior to or dur-
ing the onset of these symptoms, the patient was not
exposed to agents known to affect platelet function or
coagulation (aspirin or estrogen therapy) with the ex-
ception of ibuprofen 800 mg every 6 hours. PT (9.7 sec),
INR (1.0), and PTT (24.6 sec) levels were all within the
normal range. An emergent MRI revealed an increase
in the tumor size from 4.3 to 4.8 cm in transverse di-
mension (Fig. 1C), and the tumor was noted to herniate
through the diaphragma sellae extending up the right
sylvian fissure with a slight elevation of the right lat-
eral ventricle. Moreover, there was a dramatic loss of
homogenous contrast enhancement throughout the
bulk of the lesion. No evidence of acute hemorrhage
was noted. The patient was given 100 mg hydrocorti-
sone to reduce suspected tumor edema and 10 U of
subcutaneous dDAVP to control diabetes insipidus.
The cranial nerve palsies remained unimproved.
Cabergoline was continued at 1 mg twice a week, but
octreotide was temporarily stopped.
Two days following the onset of CSS, on December
16th, the patient experienced partial resolution of her
left VIth nerve palsy, but a noticeable decrease in facial
sensation in the V2 distribution bilaterally. Her plasma
GH had fallen to 11.3 ng/ml and her prolactin was 111
ng/ml. To control severe recurrent headaches, she was
restarted on 200 lg subcutaneous octreotide every
four hours, and continued on this regimen throughout
the remainder of her hospital stay. By the time of her
discharge on December 20th, GH and PRL levels had
fallen to 2.9 ng/ml and 51.4 ng/ml respectively (Table 1).
An MRI obtained prior to discharge (Figure 1D) re-
vealed interval changes in the tumor consistent with
necrosis and inflammation around the carotid arteries.
Following discharge, the patient was placed on a
Fig. 1. Serial coronal MRI scans of the sella tursica and cavernous sinuses with and without gadolinium contrast. A. Preoperative
MRI from September 30. B. Postoperative MRI from December 9. C. MRI scan obtained during the acute onset of CSS and DI follow-
ing octreotide therapy on December 15. D. MRI scan from December 19. E. MRI scan from January 13 following long-acting oc-
treotide therapy.
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long-acting octreotide formulation (Sandostatin LAR)
at a dose of 20 mg per month. The cavernous sinus
syndrome continued to gradually improve with resolu-
tion of diplopia and a return to normal cranial nerve
function by February of 2000. Follow-up GH and PRL
levels were 2.9 ng/ml and 280 ng/ml respectively (Table
1). An MRI obtained at that time revealed marked
involution of the macroadenoma (Fig. 1E).
Discussion
Primary transsphenoidal resection has been reported
to achieve GH levels ,5 ng/ml in 78% of patients and
adequate glucose suppression tests in 58% [13]. How-
ever, radiation and octreotide remain the principal
means of reducing the function of the residual GH se-
creting tumor that is not amenable to resection. In
addition, octreotide is an important treatment for per-
sistent severe headaches in these patients.
The major portion of a macroadenoma that is not
accessible to transsphenoidal resection is that which
invades  dura, including the cavernous sinus. Tumor
extension into the cavernous sinus allows the tumor to
encase the IIIrd, IVth, and VIth cranial nerves as well
as the 1st and 2nd divisions of the Vth cranial nerve.
CSS, a combination of palsies in this group of cranial
nerves, has been reported to result from cavernous
sinus tumors, but occurs most commonly in association
with neurovascular abnormalities of the cavernous si-
nus, neurosurgical intervention in this region, or the
Tolosa-Hunt syndrome. Commonly, the nerves of the
cavernous sinus will tolerate gradual encasement by
tumors, while abrupt changes in pressure associated
with phenomena like carotid-cavernous sinus fistulas
will invariably compromise the function of these
nerves [14].
In the present case, the acute onset of diabetes in-
sipidus and CSS followed the initiation of octreotide
therapy. MRI scans obtained before and after onset of
CSS during the postoperative period showed a dra-
matic change in the adenoma in response to octreotide.
These studies demonstrate an interval increase in size
of the adenoma involving the sella turcica, cavernous
sinuses, and suprasellar region resulting in increased
mass effect on the optic chiasm, hypothalamus, and
cavernous sinus contents. In addition, the lesion’s en-
hancement abruptly changed from a homogenous pat-
tern to a pattern of peripheral enhancement with no
internal tumor enhancement. Subsequent MRI ob-
tained 4 days later continued to show loss of tumor
enhancement and evidence of enhancement around the
carotid arteries. The MRI scan one month later showed
progressive tumor involution with long acting oc-
treotide treatment. These imaging changes are consis-
tent with tumor infarction.
In addition to MR findings, plasma GH levels are
consistent with tumor infarction. GH dramatically in-
creased immediately after the initiation of octreotide
therapy, likely as a reflection of tumor necrosis. GH
and Prolactin levels then declined significantly within
three days of octreotide initiation, and plasma GH re-
mained low despite temporary withdrawal of oc-
treotide. The necrosis of the tumor is further sug-
gested by a dramatic decline in serum prolactin despite
unchanged cabergoline dosage. Another case report
presenting the endocrine findings of a patient with a
growth hormone and prolactin producing pituitary
adenoma showed that treatment of acromegaly with a
single dose of bromocriptine caused pituitary hemor-
rhagic infarction [15]. Like the patient in the present
case, this patient showed significantly lowered GH and
PRL levels after bromocriptine administration.
It is generally assumed that octreotide reduces tu-
mor volume by a mechanism that involves shrinkage of
tumor cells [7]. This hypothesis that tumor shrinkage
is noncytolytic rests largely on morphometric studies
and on the evidence that tumor mass recurs when oc-
treotide therapy is  discontinued  [4]. In the present
case, tumor size reduction may have resulted from a
combination of ischemic necrosis and noncytolytic tu-
mor cell shrinkage. Hemorrhagic pituitary infarction
usually occurs after acute hypotension in pregnancy
(Sheehan’s syndrome) or in large pituitary tumors as a
result of “outgrowth” of blood supply. Several cases of
tumor infarction following acute stimulation have been
reported [16]. Thus, pituitary infarction may occur
when tumor blood demand exceeds blood supply. Oc-
Table 1. Summary of laboratory test results
Growth
hormone Prolactin IGF-I
Date ng/ml ng/ml ng/ml MRI

















12/19 2.9 51.4 yes
12/21 2.5 35.2
1/6 2.9 260 yes
1/13 yes
2/11 3.9 564 1173
3/24 8.9 1208
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treotide might induce infarction through a direct effect
on tumor vessels.
Vasoconstriction may represent a mechanism
whereby octreotide might induce tumor ischemia. A
double blind controlled trial has shown octreotide to be
effective in 100 lg doses against migraine headaches
raising the possibility of direct cerebrovascular effects
[17]. Octreotide is also known to reduce bleeding in
patients with variceal bleeding [18]. Other investiga-
tors have documented improvement in various vascu-
lar parameters in portal hypertension with octreotide
treatment [19]. Yamashita has demonstrated effects of
octreotide on phosphatase activity in endothelium [20].
Previous case reports have documented an associa-
tion of head trauma with pituitary hemorrhage [21,22].
These reports suggest the possibility that subtotal re-
section of the tumor may have induced trauma suffi-
cient to cause infarction and subsequent necrosis.
However, in both of these cases the pituitary apoplexy
reported was hemorrhagic. More importantly, the apo-
plectic event always occurred in close temporal prox-
imity to the trauma. In the current case, tumor in-
farction happened on post-operative day 6. Delayed
pituitary infarction following subtotal resection has
not been reported.
In summary, administration of octreotide is common
in acromegalic patients with cavernous sinus involve-
ment due to the surgical inaccessibility of such tumors.
The present case illustrates the possibility of CSS com-
plicating such treatment. In addition, the elevation in
GH levels and tumor size immediately following initia-
tion of octreotide therapy argues for a mechanism
other than GH reduction through noncytolytic tumor
cell shrinkage. A vascular effect of octreotide on soma-
totrophic tumors is one possible mechanism for such an
effect.
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